Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease
- PMID: 21827355
- DOI: 10.3109/00365513.2011.586470
Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease
Abstract
Background: YKL-40 is a glycoprotein secreted by macrophages and neutrophils in tissues with inflammation. Plasma YKL-40 is increased in patients with coronary artery disease (CAD) and associated with cardiovascular and all-cause mortality. Furthermore, plasma YKL-40 seems related to the number of diseased main vessels in patients with stable CAD. The aim was to further study the relation between YKL-40 and stenosis degree, stenosis type and actual ischemia in stable CAD patients.
Methods: Plasma YKL-40 and hsCRP levels were determined from 206 consecutive patients with stable angina pectoris admitted for coronary angiography. Plasma YKL-40 in 245 healthy subjects was used for comparison. In addition to one to three vessel stenosis scores, two new scores for evaluating coronary angiographies were established for discriminating between focal and diffuse CAD and the extent of myocardial ischemia.
Results: YKL-40 levels in CAD patients (median: 52 μg/L and quartiles: 37-85 μg/L) were significantly increased (p < 0.001) compared to the healthy controls. In univariate analyses plasma YKL-40 was significantly associated with ischemic myocardium score, age, hypertension, peripheral vascular disease and serum creatinine levels. In multivariate analyses YKL-40 was related to hsCRP, peripheral artery disease, hypertension, and statin treatment.
Conclusions: Plasma YKL-40 was increased in patients with CAD compared to controls. YKL-40 was related to the ischemic myocardium, but not to degree of CAD using different scoring systems. Therefore, YKL-40 is not related to the extent of CAD, but to some other pathophysiological mechanisms of importance for the prognosis.
Similar articles
-
Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial.Immunobiology. 2013 Jul;218(7):945-51. doi: 10.1016/j.imbio.2012.10.015. Epub 2012 Nov 7. Immunobiology. 2013. PMID: 23294528 Clinical Trial.
-
Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease.Atherosclerosis. 2010 Jun;210(2):590-5. doi: 10.1016/j.atherosclerosis.2009.12.016. Epub 2009 Dec 21. Atherosclerosis. 2010. PMID: 20056225
-
Increased YKL-40 levels in patients with isolated coronary artery ectasia: an observational study.Anadolu Kardiyol Derg. 2013 Aug;13(5):465-70. doi: 10.5152/akd.2013.145. Epub 2013 May 27. Anadolu Kardiyol Derg. 2013. PMID: 23728225
-
Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?Immunobiology. 2012 May;217(5):483-91. doi: 10.1016/j.imbio.2011.04.007. Epub 2011 Apr 30. Immunobiology. 2012. PMID: 21601307 Review.
-
YKL-40--an emerging biomarker in cardiovascular disease and diabetes.Cardiovasc Diabetol. 2009 Nov 23;8:61. doi: 10.1186/1475-2840-8-61. Cardiovasc Diabetol. 2009. PMID: 19930630 Free PMC article. Review.
Cited by
-
Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease.J Am Heart Assoc. 2020 Mar 3;9(5):e014634. doi: 10.1161/JAHA.119.014634. Epub 2020 Mar 2. J Am Heart Assoc. 2020. PMID: 32114892 Free PMC article. Clinical Trial.
-
Amelioration of atherosclerosis in apolipoprotein E-deficient mice by combined RNA interference of lipoprotein-associated phospholipase A2 and YKL-40.PLoS One. 2018 Aug 23;13(8):e0202797. doi: 10.1371/journal.pone.0202797. eCollection 2018. PLoS One. 2018. PMID: 30138439 Free PMC article.
-
Monoamine oxidase A inhibition protects the myocardium after experimental acute volume overload.Anatol J Cardiol. 2019 Jan;21(1):39-45. doi: 10.14744/AnatolJCardiol.2018.37336. Anatol J Cardiol. 2019. PMID: 30587705 Free PMC article.
-
Serum YKL-40 Levels Are Associated with the Atherogenic Index of Plasma in Children.Mediators Inflamm. 2020 Sep 26;2020:8713908. doi: 10.1155/2020/8713908. eCollection 2020. Mediators Inflamm. 2020. PMID: 33061832 Free PMC article.
-
The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test.Cardiovasc Endocrinol. 2016 Mar;5(1):21-27. doi: 10.1097/XCE.0000000000000073. Epub 2016 Jan 4. Cardiovasc Endocrinol. 2016. PMID: 28392973 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous